Quantitation of glucose uptake in tumors by dynamic FDG-PET has less glucose bias and lower variability when adjusted for partial saturation of glucose transport

EJNMMI Research

Volumn 2, Issue 1, 2012, Pages 1-13

  Williams, Simon Peter ^a   Flores Mercado, Judith E ^a   Port, Ruediger E ^a   Bengtsson, Thomas ^a  

^a GENENTECH INC   (United States)

Author keywords

Blood glucose; Dynamic FDG PET; Glucose correction; MRGlucMAX; Partial saturation correction; Variability

Indexed keywords

FLUORODEOXYGLUCOSE F 18;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; FEMALE; FLOW KINETICS; GLUCOSE BLOOD LEVEL; GLUCOSE INTAKE; GLUCOSE METABOLISM; GLUCOSE TRANSPORT; IMAGE ANALYSIS; MALE; METABOLIC RATE; MICHAELIS CONSTANT; MICHAELIS MENTEN KINETICS; MOUSE; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; QUANTITATIVE STUDY; RETROSPECTIVE STUDY; SENSITIVITY ANALYSIS; TEST RETEST RELIABILITY; TUMOR SCINTISCANNING;

EID: 84861629157     PISSN: None     EISSN: 2191219X     Source Type: Journal    
DOI: 10.1186/2191-219X-2-6     Document Type: Article

References (55)

1. Crouthamel MC, Kahana JA, Korenchuk S, Zhang SY, Sundaresan G, Eberwein DJ, Brown KK, Kumar R: Mechanism and management of AKT inhibitor-induced hyperglycemia. Clin Cancer Res: Official J Am Assoc Cancer Res 2009, 15:217-225.
2. Langen KJ, Braun U, Rota Kops E, Herzog H, Kuwert T, Nebeling B, Feinendegen LE: The influence of plasma glucose levels on fluorine-18-fluorodeoxyglucose uptake in bronchial carcinomas. J Nucl Med 1993, 34:355-359.
3. Lindholm P, Minn H, Leskinen-Kallio S, Bergman J, Ruotsalainen U, Joensuu H: Influence of the blood glucose concentration on FDG uptake in cancer-a PET study. J Nucl Med 1993, 34:1-6.
4. Huang SC: Anatomy of SUV. Standardized uptake value. Nucl Med Biol 2000, 27:643-646.
5. Keyes JW: SUV: standard uptake or silly useless value? J Nucl Med 1995, 36:1836-1839.
6. Diederichs C, Staib L, Glatting G, Beger H, Reske S: FDG PET: elevated plasma glucose reduces both uptake and detection rate of pancreatic malignancies. J Nucl Med 1998, 39:1030-1033.
7. Sokoloff L, Reivich M, Kennedy C, Des Rosiers MH, Patlak CS, Pettigrew KD, Sakurada O, Shinohara M: The [14C]deoxyglucose method for the measurement of local cerebral glucose utilization: theory, procedure, and normal values in the conscious and anesthetized albino rat. J Neurochem 1977, 28:897-916.
8. Hallett WA, Marsden PK, Cronin BF, O'Doherty MJ: Effect of corrections for blood glucose and body size on [18F]FDG PET standardised uptake values in lung cancer. Eur J Nucl Med 2001, 28:919-922.
9. Kasahara M, Hinkle PC: Reconstitution and purification of the d-glucose transporter from human erythrocytes. J Biol Chem 1977, 252:7384-7390.
10. Rivenzon-Segal D, Rushkin E, Polak-Charcon S, Degani H: Glucose transporters and transport kinetics in retinoic acid-differentiated T47D human breast cancer cells. Am J Physiol Endocrinol Metab 2000, 279: E508-519.
11. Rodriguez-Enriquez S, Marin-Hernandez A, Gallardo-Perez JC, Moreno-Sanchez R: Kinetics of transport and phosphorylation of glucose in cancer cells. J Cell Physiol 2009, 221:552-559.
12. Van Zijl PC, Davis D, Eleff SM, Moonen CT, Parker RJ, Strong JM: Determination of cerebral glucose transport and metabolic kinetics by dynamic MR spectroscopy. Am J Physiol 1997, 273:E1216-1227.
13. Cornford EM, Young D, Paxton JW, Hyman S, Farrell CL, Elliott RB: Bloodbrain glucose transfer in the mouse. Neurochem Res 1993, 18:591-597.
14. Lammertsma AA, Hoekstra CJ, Giaccone G, Hoekstra OS: How should we analyse FDG PET studies for monitoring tumour response? Eur J Nucl Med Mol Imaging 2006, 33:16-21.
15. Patlak CS, Blasberg RG, Fenstermacher JD: Graphical evaluation of bloodto-brain transfer constants from multiple-time uptake data. J Cerebral Blood Flow Metab 1983, 3:1-7.
16. Patlak CS, Blasberg RG: Graphical evaluation of blood-to-brain transfer constants from multiple-time uptake data. Generalizations. J Cereb Blood Flow Metab 1985, 5:584-590.
17. Cheebsumon P, Velasquez LM, Hoekstra CJ, Hayes W, Kloet RW, Hoetjes NJ, Smit EF, Hoekstra OS, Lammertsma AA, Boellaard R: Measuring response to therapy using FDG PET: semi-quantitative and full kinetic analysis. Eur J Nucl Med Mol Imaging 2011, 38:832-842.
18. Flores JE, Mcfarland LM, Vanderbilt A, Ogasawara AK, Williams S-P: The effects of anesthetic agent and carrier gas on blood glucose and tissue uptake in mice undergoing dynamic FDG-PET imaging: sevoflurane and isoflurane compared in air and in oxygen. Mol Imaging Biol 2008, 10:192-200.
19. Li Q, Leahy R: Statistical modeling and reconstruction of randoms precorrected PET data. IEEE Trans Med Imaging 2006, 25:1565-1572.
20. Bao Q, Newport D, Chen M, Stout DB, Chatziioannou AF: Performance evaluation of the inveon dedicated PET preclinical tomograph based on the NEMA NU-4 standards. J Nucl Med 2009, 50:401-408.
21. Green L, Gambhir S, Srinivasan A, Banerjee P, Hoh C, Cherry S, Sharfstein S, Barrio J, Herschman H, Phelps M: Noninvasive methods for quantitating blood time-activity curves from mouse PET images obtained with fluorine-18-fluorodeoxyglucose. J Nucl Med 1998, 39:729-734.
22. Meyer PT, Circiumaru V, Cardi CA, Thomas DH, Bal H, Acton PD: Simplified quantification of small animal [18F]FDG PET studies using a standard arterial input function. Eur J Nucl Med Mol Imaging 2006, 33:948-954.
23. R Development Core Team: R: A Language and Environment for Statistical Computing Vienna: R Foundation for Statistical Computing; 2011.
24. Logan J: Graphical analysis of PET data applied to reversible and irreversible tracers. Nucl Med Biol 2000, 27:661-670.
25. Doot RK, Dunnwald LK, Schubert EK, Muzi M, Peterson LM, Kinahan PE, Kurland BF, Mankoff DA: Dynamic and static approaches to quantifying 18F-FDG uptake for measuring cancer response to therapy, including the effect of granulocyte CSF. J Nucl Med 2007, 48:920-925.
26. Krohn KA, Mankoff DA, Muzi M, Link JM, Spence AM: True tracers: comparing FDG with glucose and FLT with thymidine. Nucl Med Biol 2005, 32:663-671.
27. Cornish-Bowden A: Fundamentals of Enzyme Kinetics London: Portland Press; 2004.
28. Michaelis L, Menten ML: Die kinetik der invertinwirkung. Biochemische Zeitschrift 1913, 49:333-369.
29. Weber WA, Schwaiger M, Avril N: Quantitative assessment of tumor metabolism using FDG-PET imaging. Nucl Med Biol 2000, 27:683-687.
30. Phelps ME, Huang SC, Hoffman EJ, Selin C, Sokoloff L, Kuhl DE: Tomographic measurement of local cerebral glucose metabolic rate in humans with (F-18)2-fluoro-2-deoxy-d-glucose: validation of method. Ann Neurol 1979, 6:371-388.
31. Phelps ME, Schelbert HR, Hoffman EJ, Huang SC, Kuhl DE: Positron tomography of the heart. Prog Nucl Med 1980, 6:183-209.
32. de Geus-Oei L-F, Visser EP, Krabbe PFM, van Hoorn BA, Koenders EB, Willemsen AT, Pruim J, Corstens FHM, Oyen WJG: Comparison of imagederived and arterial input functions for estimating the rate of glucose metabolism in therapy-monitoring 18F-FDG PET studies. J Nucl Med 2006, 47:945-949.
33. Eary JF, Conrad EU, Bruckner JD, Folpe A, Hunt KJ, Mankoff DA, Howlett AT: Quantitative [F-18]fluorodeoxyglucose positron emission tomography in pretreatment and grading of sarcoma. Clin Cancer Res 1998, 4:1215-1220.
34. Hawkins RA, Choi Y, Huang SC, Messa C, Hoh CK, Phelps ME: Quantitating tumor glucose metabolism with FDG and PET. J Nucl Med 1992, 33:339-344.
35. Hunter GJ, Hamberg LM, Alpert NM, Choi NC, Fischman AJ: Simplified measurement of deoxyglucose utilization rate. J Nucl Med 1996, 37:950-955.
36. Vriens D, De Geus-Oei LF, Van Laarhoven HWM, Van Der Heijden HFM, Krabbe PFM, Visser EP, Oyen WJG: Comparison of two region of interest definition methods for metabolic response evaluation with [18F]FDGPET. Q J Nucl Med Mol Imaging 2010, 54:677-688.
37. Dette H, Biedermann S: Robust and efficient designs for the Michaelis-Menten model. J Am Stat Assoc 2003, 98:679-686.
38. Raaijmakers JGW: Statistical analysis of the Michaelis-Menten equation. Biometrics 1987, 43:793-803.
39. Ruppert D, Cressie N, Carroll RJ: A transformation weighting model for estimating Michaelis-Menten parameters. Biometrics 1989, 45:637-656.
40. Burrows RC, Freeman SD, Charlop AW, Wiseman RW, Adamsen TC, Krohn KA, Spence AM: [18F]-2-fluoro-2-deoxyglucose transport kinetics as a function of extracellular glucose concentration in malignant glioma, fibroblast and macrophage cells in vitro. Nucl Med Biol 2004, 31:1-9.
41. Aussedat B, Dupire-Angel M, Gifford R, Klein JC, Wilson GS, Reach G: Interstitial glucose concentration and glycemia: implications for continuous subcutaneous glucose monitoring. Am J Physiol Endocrinol Metab 2000, 278:E716-728.
42. Thennadil SN, Rennert JL, Wenzel BJ, Hazen KH, Ruchti TL, Block MB: Comparison of glucose concentration in interstitial fluid, and capillary and venous blood during rapid changes in blood glucose levels. Diabetes Technol Ther 2002, 3:357-365.
43. Cengiz E, Tamborlane WV: A tale of two compartments: interstitial versus blood glucose monitoring. Diabetes Technol Ther 2009, 11:S11-16.
44. Gullino PM, Clark SH, Grantham FH: The interstitial fluid of solid tumors. Cancer Res 1964, 24:780-794.
45. Wahl R, Henry C, Ethier S: Serum glucose: effects on tumor and normal tissue accumulation of 2-[F-18]-fluoro-2-deoxy-d-glucose in rodents with mammary carcinoma. Radiology 1992, 183:643-647.
46. Torizuka T, Fisher S, Wahl R: Insulin-induced hypoglycemia decreases uptake of 2-[F-18]fluoro-2-deoxy-d-glucose into experimental mammary carcinoma. Radiology 1997, 203:169-172.
47. Zhuang HM, Cortes-Blanco A, Pourdehnad M, Adam LE, Yamamoto AJ, Martinez-Lazaro R, Lee JH, Loman JC, Rossman MD, Alavi A: Do high glucose levels have differential effect on FDG uptake in inflammatory and malignant disorders? Nucl Med Commun 2001, 22:1123-1128.
48. Gorenberg M, Hallett WA, O'Doherty MJ: Does diabetes affect [(18)F]FDG standardised uptake values in lung cancer? Eur J Nucl Med Mol Imaging 2002, 29:1324-1327.
49. Christensen R: Plane Answers to Complex Questions: The Theory of Linear Models New York: Springer; 1987.
50. van Belle G, Martin DC: Sample size as a function of coefficient of variation and ratio of means. Am Statistician 1993, 47:165-167.
51. Weber WA: Quantitative analysis of PET studies. Radiother Oncol 2010, 96:308-310.
52. Dandekar M, Tseng J, Gambhir S: Reproducibility of 18F-FDG microPET studies in mouse tumor xenografts. J Nucl Med 2007, 48:602-607.
53. Weber WA, Ziegler SI, Thodtmann R, Hanauske AR, Schwaiger M: Reproducibility of metabolic measurements in malignant tumors using FDG PET. J Nucl Med 1999, 40:1771-1777.
54. Wong CY, Thie J, Parling-Lynch KJ, Zakalik D, Margolis JH, Gaskill M, Hill J, Qing F, Fink-Bennett D, Nagle C: Glucose-normalized standardized uptake value from (18)F-FDG PET in classifying lymphomas. J Nucl Med: Official Publ, Soc Nucl Med 2005, 46:1659-1663.
55. Dunn JT, Anthony K, Amiel SA, Marsden PK: Correction for the effect of rising plasma glucose levels on quantification of MR(glc) with FDG-PET. J Cereb Blood Flow Metab 2009, 29:1059-1067.